COMMUNIQUÉS West-GlobeNewswire

Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
30/10/2026
PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congress of Neurological [...]
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
30/10/2026
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
30/10/2026
Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes [...]
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
30/10/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 30, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today welcomed a significant development in the U.S. regulatory landscape for [...]
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
30/10/2026
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized, double-blind n=90 Part A [...]
Atsena Therapeutics Reports New Preclinical Data Demonstrating Robust MYO7A Expression and Favorable Safety for ATSN-301, a Laterally Spreading Dual AAV Vector-based Gene Therapy for Usher Syndrome Type 1B
30/10/2026
Dual vector and AAV.SPR technologies combine to drive supraphysiological levels of full-length MYO7A in non-human primate retina, reaching the macula without foveal detachment Six-month GLP toxicology study establishes [...]
Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association
30/10/2026
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders [...]
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
30/10/2026
Redesigned site brings together information on BGLC’s operating businesses, healthcare initiatives and public disclosures KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC [...]
Femasys Appoints John Moorhead to Board of Directors
30/10/2026
ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the [...]
Press Release Biocartis NV: Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026
30/10/2026
PRESS RELEASE, October 30, 2026 – 08:00 CDT Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026 ITASCA, IL, US – October 30, 2026. Today, Biocartis , an innovative [...]
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
30/10/2026
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax [...]
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
30/10/2026
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation Satyajit Mitra, Executive Director, Head of Oncology, to discuss [...]
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
30/10/2026
Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary [...]
NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage
30/10/2026
500 Patients, 30 Hospitals, 3 Countries is Part of the Setup DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com ) — In a market where the latest whizbang trends often dominate investor attention, NeOnc [...]
Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace
30/10/2026
An Equipment Innovator’s Interest in Kraig’s High Tech Fibers Indicates Potential Applications for Lightweight and/or Tough Materials, and Possibly Elevate Project Atlas DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( www. [...]
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
30/10/2026
First FDA-approved biologic specifically designed to cross blood-brain barrier wins award dedicated to exceptional scientific leadership and transformational impact on patient care First new FDA-approved treatment [...]
Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
30/10/2026
The Phase III AIRWARD™ trial was published today on ClinicalTrials.gov (NCT07907991). 1 AIRWARD will evaluate the efficacy and safety of verducatib, an investigational oral therapy for COPD. 1 The Phase III trial will [...]
Halloween Peptide Sale 2026: Kylo Peptides Announces $1 Research Vial Sale With Orders of $200 or More
30/10/2026
SHERIDAN, Wyo., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ], a U.S. research peptides supplier, today announced a limited-time Halloween sale. Customers who place an order of $200 or [...]
Tangram annonce l’administration du TGM-148 au premier participant de l’essai de phase 1 évaluant le TGM-148, un nouveau médicament expérimental à ARNi contre les troubles hémorragiques
30/10/2026
Le TGM-148 est conçu pour associer une efficacité hémostatique à un profil de sécurité favorable et une faible contrainte thérapeutique Le deuxième actif de Tangram à entrer en phase clinique en 2026 L’essai de phase 1 [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum